How Does Dermovate Work? Clobetasol Propionate Explained

What is Dermovate?

Dermovate is a branded topical corticosteroid manufactured by GlaxoSmithKline (GSK) and available in the UK as a cream, ointment, and scalp application. Its active ingredient, clobetasol propionate 0.05%, is a synthetic glucocorticoid that belongs to the very potent (Class 4) category on the UK’s four-tier potency classification system. No other class of topical steroid is stronger.

The medicine is licensed in the UK for the short-term treatment of severe, resistant inflammatory skin conditions in adults. Because of its potency, Dermovate is a prescription-only medicine (POM) and is subject to tighter prescribing controls than weaker topical steroids such as hydrocortisone (Class 1) or betamethasone valerate 0.1% (Class 3). It should only be prescribed when the clinical picture justifies its use, and always within strict duration and quantity limits.

Clobetasol propionate was first developed in the 1970s and remains a clinically important option for dermatologists and GPs managing conditions that do not respond adequately to moderately potent or potent steroids. Despite its age, it continues to feature in the British National Formulary (BNF) and in NICE clinical knowledge summaries as a first-line option for specific severe dermatoses.

Conditions Dermovate Treats

Dermovate is indicated for severe or resistant inflammatory skin conditions where inflammation has not responded satisfactorily to a less potent topical corticosteroid. The Summary of Product Characteristics (SPC) published on the Electronic Medicines Compendium lists the following main indications:

• Severe atopic eczema (atopic dermatitis) — particularly thick, lichenified, or chronic plaques that have not cleared with potent steroids such as betamethasone valerate
• Discoid (nummular) eczema — coin-shaped patches of intensely inflamed skin
• Plaque psoriasis (excluding widespread plaque psoriasis) — well-defined, scaly plaques on the body or scalp
• Lichen planus — a chronic inflammatory condition producing flat-topped, itchy papules
• Discoid lupus erythematosus — a chronic skin form of lupus characterised by scarring, inflamed plaques
• Other severe, resistant inflammatory dermatoses where the prescribing clinician judges that the benefit of a very potent steroid outweighs the risk

Dermovate is not intended for mild or moderate eczema, nor for inflammatory conditions that respond to weaker preparations. The guiding principle in UK prescribing practice is to use the least potent effective preparation — stepping up to very potent agents only when clinically necessary. Where a moderate or potent steroid has already been tried and found insufficient, Dermovate represents an appropriate and well-evidenced escalation.

How Dermovate Works: The Mechanism

Clobetasol propionate works through several overlapping anti-inflammatory and vasoconstrictive pathways, all mediated through intracellular glucocorticoid receptors. Understanding this mechanism explains both why Dermovate is effective for severe disease and why misuse carries real risk.

Glucocorticoid Receptor Binding

When Dermovate is applied topically, clobetasol propionate penetrates the stratum corneum (the outermost layer of skin) and enters keratinocytes, fibroblasts, and immune cells within the dermis and epidermis. Once inside the cell, it binds with high affinity to cytoplasmic glucocorticoid receptors (GR-alpha). Clobetasol propionate has a particularly high receptor binding affinity compared to other topical steroids, which is the principal reason for its very potent classification.

After binding, the drug–receptor complex translocates into the cell nucleus, where it acts as a transcription factor — directly modulating the expression of hundreds of genes involved in the inflammatory response.

Suppression of Pro-Inflammatory Cytokines

One of the most clinically significant actions of activated glucocorticoid receptors is the suppression of pro-inflammatory cytokine production. In eczema and other inflammatory dermatoses, the skin is flooded with immune signalling molecules that drive redness, swelling, and itch. Clobetasol propionate suppresses the transcription and release of key mediators including:

• Interleukin-1 (IL-1) — a potent activator of the inflammatory cascade
• Interleukin-2 (IL-2) — a T-cell growth factor that perpetuates the immune response
• Tumour necrosis factor-alpha (TNF-α) — a master pro-inflammatory cytokine that amplifies skin inflammation
• Interleukin-4 and Interleukin-13 — key drivers of the Th2-biased immune response characteristic of atopic eczema

By reducing the production of these signals, Dermovate effectively dampens the runaway immune activity that causes the visible and symptomatic features of inflammatory skin disease.

Inhibition of Prostaglandins and Leukotrienes

Glucocorticoids also upregulate the production of lipocortin-1 (annexin A1), a protein that inhibits the enzyme phospholipase A2. This enzyme is responsible for releasing arachidonic acid from cell membranes — the precursor to both prostaglandins and leukotrienes, two families of lipid mediators that contribute significantly to the heat, pain, and swelling of inflamed skin. By blocking this upstream step in the arachidonic acid cascade, clobetasol propionate reduces the production of these eicosanoids far more comprehensively than non-steroidal anti-inflammatory agents, which typically target only one branch of the cascade.

Vasoconstriction and Reduced Capillary Permeability

Clobetasol propionate also exerts a direct vasoconstrictive effect on dermal blood vessels. This reduces capillary dilatation and permeability, limiting the extravasation of fluid and immune cells into the skin. The visible result is a reduction in the characteristic redness (erythema) and oedema (swelling) of inflamed skin. This vasoconstrictive property is also the basis of the standard assay used to rank topical steroid potency — the McKenzie–Stoughton vasoconstriction assay — discussed in the next section.

Reduced Mast Cell and Dendritic Cell Activity

Beyond cytokine suppression, topical glucocorticoids reduce the number and activity of mast cells and Langerhans cells (dendritic cells) in the epidermis. Mast cells are the main source of histamine, which drives the intense pruritus (itch) characteristic of eczema. By suppressing mast cell activity, Dermovate provides significant itch relief alongside its anti-inflammatory effects, breaking the destructive itch–scratch cycle that worsens the skin barrier in atopic disease.

Potency Classification: The UK 4-Class Scale

In the United Kingdom, topical corticosteroids are classified into four potency groups based on their vasoconstrictive activity, as measured by the McKenzie–Stoughton vasoconstriction assay. This standardised test measures the degree of skin blanching produced by a given concentration of steroid under standard conditions — the greater the blanching, the higher the potency. The four classes are:

In vasoconstriction assays, clobetasol propionate is approximately 600 times more potent than hydrocortisone 1% and approximately 2–3 times more potent than betamethasone valerate 0.1% (Betnovate). That difference in potency is what makes Dermovate effective where Class 3 preparations fail — and also demands careful, time-limited use to minimise the risk of local and systemic side effects.

The UK 4-class system differs from the 7-class US classification system, where clobetasol propionate sits in Class 1 (the strongest). When reading international literature, this distinction matters to avoid confusion about relative potency rankings.

Dermovate Formulations

Dermovate is available in three formulations, each suited to a different clinical context. The choice of formulation depends largely on the nature and location of the skin lesion being treated.

Dermovate Cream

The cream formulation contains clobetasol propionate 0.05% in a water-miscible base. It is particularly suited to moist, weeping, or acutely inflamed eczema where an ointment would feel too greasy or occlude excessive exudate. The cream is also more cosmetically acceptable for daytime use. For detailed guidance on using the cream formulation in eczema, see our article on Dermovate cream for eczema.

Dermovate Ointment

The ointment formulation uses a greasy, water-free base that provides a greater degree of skin hydration and occlusion than the cream. It is the preferred choice for dry, thickened (lichenified), or chronic plaques where enhanced penetration through a thickened stratum corneum is needed. The ointment’s occlusivity also increases the bioavailability of clobetasol propionate in the skin. Full guidance on the ointment’s use appears in our companion article on Dermovate ointment for dry and lichenified skin.

Dermovate Scalp Application

The scalp application is an alcohol-based lotion formulated to penetrate through hair to the scalp surface. It is used for inflammatory conditions affecting the scalp, including scalp psoriasis and severe seborrhoeic dermatitis that has not responded to milder preparations. The liquid consistency allows easier application without matting the hair.

Safe Usage Guidelines

Because of its very high potency, Dermovate must be used exactly as directed. The following guidance is drawn from the product SPC, the BNF, NICE CKS, and NHS patient safety information. Deviating from these instructions — even with a genuine intention to speed recovery — substantially increases the risk of local and systemic side effects.

How to Apply Dermovate

Side Effects of Dermovate

Like all very potent corticosteroids, Dermovate carries a range of potential side effects. These divide into local (skin) side effects — which become more likely with prolonged or excessive use — and systemic side effects, which are rare but serious, arising from absorption of clobetasol propionate into the bloodstream.

Local Side Effects

Local adverse effects are a direct consequence of the anti-proliferative action of glucocorticoids on skin cells. With appropriate short-term use within the recommended quantity and duration, the risk is low. Prolonged use significantly increases these risks:

• Skin thinning (cutaneous atrophy): Glucocorticoids inhibit fibroblast proliferation and reduce collagen synthesis, causing the skin to become thinner, more fragile, and prone to easy bruising. This effect is most pronounced on already thin skin and in areas of occlusion.
• Striae distensae (stretch marks): Dermal atrophy can result in permanent stretch marks, particularly when Dermovate is used in skin folds or over joints. These are largely irreversible.
• Telangiectasia: Prolonged vasoconstriction followed by rebound dilatation, combined with dermal thinning, can cause permanent visible dilatation of superficial blood vessels.
• Perioral dermatitis: A rosacea-like papulopustular rash around the mouth and nose, strongly associated with facial application of potent steroids.
• Hypertrichosis: Localised increased hair growth at the application site has been reported, particularly with prolonged use.
• Hypopigmentation: Temporary or permanent reduction in skin pigmentation can occur, particularly in patients with darker skin tones.
• Contact sensitisation: Although rare, patients can develop a contact allergy to clobetasol propionate itself or to excipients in the formulation. This presents as a worsening rash despite continued treatment.
• Rebound flare: Abrupt withdrawal after prolonged use can cause a rebound worsening of the underlying condition. Tapering or stepping down to a less potent preparation is preferred over sudden discontinuation.

Systemic Side Effects

Systemic effects arise when sufficient clobetasol propionate is absorbed through the skin to exert effects on organs distant from the application site. While rare with appropriate use, the risk increases substantially with large quantities, occlusion, long duration, or use on thin or broken skin:

• Hypothalamic–pituitary–adrenal (HPA) axis suppression: Exogenous glucocorticoids signal the hypothalamus and pituitary to reduce production of corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH), which in turn reduces the adrenal glands’ own cortisol output. With sustained suppression, the adrenal glands may be unable to mount an adequate stress response, creating a state of secondary adrenal insufficiency.
• Adrenal suppression and Addisonian crisis: Severe or prolonged HPA suppression can, in exceptional cases, cause an Addisonian-type crisis — a rare but potentially life-threatening emergency characterised by severe hypotension, hypoglycaemia, and circulatory collapse. This is most likely to occur if the medicine is used far beyond recommended quantities and durations.
• Cushingoid features: With very excessive use, patients may develop signs resembling Cushing’s syndrome — including central weight gain, moon face, and buffalo hump.
• Growth suppression in children: Because children have a higher skin surface area-to-body-weight ratio, they are at considerably greater risk of systemic absorption. Dermovate is not licensed for use in children under 18 years of age except under specialist supervision.
• Raised intraocular pressure / glaucoma and posterior subcapsular cataracts: These are rare but recognised risks if the product is applied near the eyes or if there is significant systemic absorption.

Who Should Not Use Dermovate

There are several absolute and relative contraindications to the use of Dermovate. These are set out in the product SPC and align with general BNF and NICE guidance on the appropriate use of very potent topical corticosteroids.

Dermovate must not be used in the following situations:

• Children under 18 years without specialist supervision — due to the greatly increased risk of systemic absorption and adrenal suppression in paediatric patients
• Skin infections (bacterial, fungal, or viral) — including impetigo, tinea (ringworm), candidiasis, herpes simplex, chickenpox, and molluscum contagiosum. Topical corticosteroids suppress the immune response in the skin, potentially allowing infections to spread unchecked. If infection is present, it must be treated first; combined steroid/antimicrobial preparations may be appropriate in some cases.
• Acne vulgaris — topical steroids worsen acne and can trigger steroid acne (acneiform eruption)
• Rosacea — potent topical steroids cause and perpetuate rosacea; their use is contraindicated
• Perioral dermatitis — topical steroids are a primary cause of this condition; their use will worsen it
• Known allergy to clobetasol propionate or any excipient in the Dermovate formulation
• Pregnancy and breastfeeding — Dermovate should be used with great caution during pregnancy and is not recommended for use on the breast when breastfeeding, due to the risk of neonatal exposure. Use should be limited to the minimum effective amount for the shortest possible time under medical supervision.

Dermovate vs Betnovate: When to Step Up or Step Down

One of the most common clinical questions about Dermovate concerns its relationship with Betnovate (betamethasone valerate 0.1%), the Class 3 potent topical steroid that is the most widely prescribed topical steroid for moderate-to-severe eczema and psoriasis in the UK. Understanding when to use each preparation — and crucially, when to step up from Betnovate to Dermovate or step down in the reverse direction — is central to safe steroid use.

When to use Betnovate: Betnovate is the appropriate first choice when mild or moderate eczema has not responded to hydrocortisone or clobetasone butyrate. It is suitable for most body sites (excluding the face, genitals, and skin folds without supervision) and is widely used for moderate-to-severe atopic eczema flares in adults.

When to step up to Dermovate: Escalation to Dermovate is clinically justified when a full, adequate course of a potent preparation like Betnovate has been tried and has not produced adequate control. In practice, this means an area of skin that remains significantly inflamed, thickened, or symptomatic after two to four weeks of correctly applied Betnovate. The decision to prescribe Dermovate should be made or endorsed by a GP or dermatologist who has reviewed the clinical picture.

Stepping down after a Dermovate course: After achieving control with Dermovate, it is important not to continue the very potent preparation indefinitely. A step-down strategy — transitioning back to a Class 3 preparation like Betnovate or to an emollient-only regimen once the acute flare is controlled — reduces the risk of the skin-thinning and systemic effects associated with long-term very potent steroid use. For more information, see our guide on Betnovate for eczema — the potent Class 3 option.

Getting Dermovate Online via Access Doctor

Dermovate is a prescription-only medicine and cannot be legally purchased in the UK without a valid prescription issued by a registered prescriber. Access Doctor is a GPhC-registered online pharmacy (registration number 9011198) that operates a clinically governed prescribing service staffed by UK-registered doctors.

You complete a structured online consultation covering your skin condition’s history — previous treatments tried, current medications, and any contraindications. A UK-licensed doctor reviews your responses and, if clinically appropriate, issues a prescription. Your medication is then dispensed from our GPhC-registered pharmacy and dispatched to your address via tracked delivery, or you can request electronic transfer to your local pharmacy.

Our clinicians follow NICE CKS and BNF guidance in prescribing decisions. Dermovate will only be prescribed where the clinical evidence supports its use — that is, where a severe or resistant inflammatory dermatosis has failed to respond adequately to less potent preparations. We do not issue prescriptions for very potent steroids as a first-line treatment where a milder preparation would be appropriate.